MX2017003546A - Tratamiento y curacion fucional de la infeccion por vih por anticuerpos monoclonales para cd4, que median la inhibicion competitiva de la entrada de vih. - Google Patents

Tratamiento y curacion fucional de la infeccion por vih por anticuerpos monoclonales para cd4, que median la inhibicion competitiva de la entrada de vih.

Info

Publication number
MX2017003546A
MX2017003546A MX2017003546A MX2017003546A MX2017003546A MX 2017003546 A MX2017003546 A MX 2017003546A MX 2017003546 A MX2017003546 A MX 2017003546A MX 2017003546 A MX2017003546 A MX 2017003546A MX 2017003546 A MX2017003546 A MX 2017003546A
Authority
MX
Mexico
Prior art keywords
treatment
monoclonal antibodies
mediating
hiv
functional cure
Prior art date
Application number
MX2017003546A
Other languages
English (en)
Inventor
Yi Wang Chang
Original Assignee
Ubi Ip Holdings
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ubi Ip Holdings filed Critical Ubi Ip Holdings
Publication of MX2017003546A publication Critical patent/MX2017003546A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente descripción se dirige a composiciones y métodos para la prevención, tratamiento y/o curación funcional de la infección por VIH. Un aspecto de la presente descripción se relaciona con anticuerpos monoclonales dirigidos contra CD4, composiciones de los mismos, y métodos que emplean estas composiciones para la prevención, tratamiento y curación funcional de la infección por VIH.
MX2017003546A 2014-09-16 2014-11-11 Tratamiento y curacion fucional de la infeccion por vih por anticuerpos monoclonales para cd4, que median la inhibicion competitiva de la entrada de vih. MX2017003546A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462051200P 2014-09-16 2014-09-16
PCT/US2014/065048 WO2016043788A1 (en) 2014-09-16 2014-11-11 Treatment and functional cure of hiv infection by monoclonal antibodies to cd4 mediating competitive hiv entry inhibition

Publications (1)

Publication Number Publication Date
MX2017003546A true MX2017003546A (es) 2017-08-14

Family

ID=55533661

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017003546A MX2017003546A (es) 2014-09-16 2014-11-11 Tratamiento y curacion fucional de la infeccion por vih por anticuerpos monoclonales para cd4, que median la inhibicion competitiva de la entrada de vih.

Country Status (14)

Country Link
US (1) US11180555B2 (es)
EP (1) EP3194442A4 (es)
JP (2) JP6716544B2 (es)
KR (1) KR20170054478A (es)
CN (1) CN107074944A (es)
AU (2) AU2014406462A1 (es)
BR (1) BR112017005134A2 (es)
CA (1) CA2961464A1 (es)
MX (1) MX2017003546A (es)
RU (1) RU2762315C2 (es)
SG (1) SG11201702056YA (es)
TW (1) TWI695720B (es)
WO (1) WO2016043788A1 (es)
ZA (1) ZA201701856B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019534891A (ja) * 2016-08-13 2019-12-05 ユナイテッド バイオファーマ、インク．Ｕｎｉｔｅｄ Ｂｉｏｐｈａｒｍａ， Ｉｎｃ． Ｈａａｒｔ安定化患者におけるｃｄ４に対する抗体によるｈｉｖ感染症の処置および持続的ウイルス学的寛解
SG11202007815TA (en) * 2018-03-05 2020-09-29 Oncoimmune Inc Methods of use of soluble cd24 for treating acquired immune deficiency syndrome (hiv/aids)
EP4090348A4 (en) * 2020-01-13 2024-05-15 The Regents of The University of California METHODS FOR TREATING VIRAL INFECTIONS

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4381295A (en) 1979-04-26 1983-04-26 Ortho Pharmaceutical Corporation Monoclonal antibody to human helper T cells and methods of preparing same
DE3828582A1 (de) 1988-08-23 1990-03-01 Max Planck Gesellschaft Monoklonaler antikoerper zur inhibierung der infektion von zellen durch hiv-viren
EP0365209A3 (en) 1988-10-17 1990-07-25 Becton, Dickinson and Company Anti-leu 3a amino acid sequence
JPH0725794B2 (ja) 1990-03-23 1995-03-22 呉羽化学工業株式会社 新規なペプチド
DE69126301T2 (de) 1990-11-27 1998-01-02 Biogen, Inc., Cambridge, Mass. Hiv-induzierte synzytien blockierender anti-cd-4-antikörper
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
JPH06125783A (ja) 1991-12-28 1994-05-10 Chemo Sero Therapeut Res Inst 組換え抗ｈｉｖ抗体およびその調製方法
CA2185116A1 (en) 1994-03-08 1995-09-14 Thomas P. Wallace Recombinant humanized anti-fb5 antibodies
US5961976A (en) 1996-06-03 1999-10-05 United Biomedical, Inc. Antibodies against a host cell antigen complex for pre- and post-exposure protection from infection by HIV
US5962319A (en) 1997-05-19 1999-10-05 Bml, Inc. Human-Th1-specific protein, gene encoding the protein, transformants, recombinant vectors, and antibodies related to the gene
JP3231262B2 (ja) 1996-06-05 2001-11-19 株式会社ビー・エム・エル ヒトＴｈ１特異的タンパク質及びこれをコードする遺伝子、並びにこれに関連する形質転換体、組換えベクター及び抗体
JPH10155489A (ja) 1996-11-27 1998-06-16 Asahi Chem Ind Co Ltd 組換え抗体及びそれをコードする核酸
JP2002512624A (ja) 1997-05-21 2002-04-23 バイオベーション リミテッド 非免疫原性タンパク質の製造方法
US6051228A (en) * 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
KR20010043797A (ko) 1998-05-25 2001-05-25 아사히 메디칼 가부시키가이샤 세포 분리 장치 및 분리 방법
US6090388A (en) 1998-06-20 2000-07-18 United Biomedical Inc. Peptide composition for prevention and treatment of HIV infection and immune disorders
WO2000051631A2 (en) 1999-03-02 2000-09-08 Schering Corporation Pegylated alpha interferon for hiv therapy
ES2301716T3 (es) 2001-12-11 2008-07-01 Biotectid Gmbh Utilizacion de un ligando marcado con especificidad para la molecula de cd4 humana, para la preparacion de un agente de diagnostico destinado al analisis de modelos de migracion y/o distribucion de poblaciones de celulas.
JP2003327536A (ja) 2002-03-07 2003-11-19 Kitasato Inst:The ヒト免疫不全症候群ウイルスの感染、増殖抑制剤
US20030211470A1 (en) 2002-03-15 2003-11-13 Olson William C. CD4-IgG2-based salvage therapy of HIV-1 infection
US7501494B2 (en) * 2003-01-15 2009-03-10 United Biomedical, Inc. Designed deimmunized monoclonal antibodies for protection against HIV exposure and treatment of HIV infection
KR100633856B1 (ko) * 2005-07-08 2006-10-13 조통래 산소와 오존을 함유한 미세기포가 녹아 있는 작물의병해충방제제
WO2007094983A2 (en) 2006-02-03 2007-08-23 Tanox, Inc. Methods and compositions for the inhibition of hiv infection of t cells
EP2150562A1 (en) * 2007-04-27 2010-02-10 Genetech, Inc. Potent, stable and non-immunosuppressive anti-cd4 antibodies

Also Published As

Publication number Publication date
ZA201701856B (en) 2020-08-26
JP2020097569A (ja) 2020-06-25
BR112017005134A2 (pt) 2017-12-12
AU2021203071A1 (en) 2021-06-17
US11180555B2 (en) 2021-11-23
TWI695720B (zh) 2020-06-11
TW201611845A (en) 2016-04-01
EP3194442A1 (en) 2017-07-26
SG11201702056YA (en) 2017-04-27
RU2017112967A3 (es) 2018-10-17
KR20170054478A (ko) 2017-05-17
US20170369576A1 (en) 2017-12-28
JP6716544B2 (ja) 2020-07-01
EP3194442A4 (en) 2018-05-23
RU2017112967A (ru) 2018-10-17
CN107074944A (zh) 2017-08-18
CA2961464A1 (en) 2016-03-24
AU2014406462A1 (en) 2017-04-06
JP2017529355A (ja) 2017-10-05
WO2016043788A1 (en) 2016-03-24
RU2762315C2 (ru) 2021-12-17

Similar Documents

Publication Publication Date Title
EA201891200A1 (ru) Композиции, содержащие бактериальные штаммы
MX2023003461A (es) Tratamiento de infeccion por clostridium difficile.
PH12017500207B1 (en) Indoles for use in influenza virus infection
MX2019001814A (es) Tratamiento y remision virologica sostenida de infeccion de vih mediante anticuerpos a cd4 en pacientes estabilizados con haart.
EA201791460A1 (ru) N4-гидроксицитидин и связанные с ним производные и варианты противовирусного применения
EA201890048A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890047A1 (ru) Композиции, содержащие бактериальные штаммы
EA201891910A1 (ru) Гетероарильные ингибиторы pad4
EA201791305A1 (ru) Конденсированные пиримидины для лечения вич
EA030115B9 (ru) Новые 6-конденсированные гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
MX2018010295A (es) Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos.
MX2023004969A (es) Metodos para tratar y prevenir infeccion por c. difficile.
EA201790571A1 (ru) Пирролопиримидины для применения при инфекции, вызванной вирусом гриппа
EA201691472A1 (ru) Конденсированные пиримидины в качестве ингибиторов комплекса p97
MX2019013808A (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer.
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
EA201891347A1 (ru) Аза-бензимидазольные ингибиторы pad4
MX2016013362A (es) Nuevos compuestos macrociclicos.
PH12017500459A1 (en) Azetidinyloxyphenylpyrrolidine compounds
MX2017004819A (es) Metodos de tratamiento de transtornos urológicos usando sarm.
EA201690594A1 (ru) Состав для лечения вич-инфекции на основе атазанавира и кобицистата
TW201611845A (en) Treatment and functional cure of HIV infection by monoclonal antibodies to CD4 mediating competitive HIV entry inhibition
MX2019002017A (es) Derivados de sofosbuvir para el tratamiento de la hepatitis c.
MX2017002093A (es) Terapia con anticuerpos para vih como sustituto de tratamiento.
EA201790851A1 (ru) Способы предотвращения, уменьшения и лечения макулодистрофии